TY - JOUR
T1 - Real time and label free profiling of clinically relevant exosomes
AU - Sina, Abu Ali Ibn
AU - Vaidyanathan, Ramanathan
AU - Dey, Shuvashis
AU - Carrascosa, Laura G.
AU - Shiddiky, Muhammad J.A.
AU - Trau, Matt
N1 - Funding Information:
This work was supported by the UQ Postdoctoral Research Fellowship (2012001456) awarded for LGC, ARCDP (DP120102503) and National Breast Cancer Foundation of Australia (CG-08-07 and CG-12-07) for MT. These grants have significantly contributed to the environment to stimulate the research described here. We also acknowledge the Queensland node of Australian National Fabrication Facility (ANFF) for SPR chip fabrication.
PY - 2016/7/28
Y1 - 2016/7/28
N2 - Tumor-derived exosomes possess significant clinical relevance due to their unique composition of genetic and protein material that is representative of the parent tumor. Specific isolation as well as identification of proportions of these clinically relevant exosomes (CREs) from biological samples could help to better understand their clinical significance as cancer biomarkers. Herein, we present a simple approach for quantification of the proportion of CREs within the bulk exosome population isolated from patient serum. This proportion of CREs can potentially inform on the disease stage and enable non-invasive monitoring of inter-individual variations in tumor-receptor expression levels. Our approach utilises a Surface Plasmon Resonance (SPR) platform to quantify the proportion of CREs in a two-step strategy that involves (i) initial isolation of bulk exosome population using tetraspanin biomarkers (i.e., CD9, CD63), and (ii) subsequent detection of CREs within the captured bulk exosomes using tumor-specific markers (e.g., human epidermal growth factor receptor 2 (HER2)). We demonstrate the isolation of bulk exosome population and detection of as low as 10% HER2(+) exosomes from samples containing designated proportions of HER2(+) BT474 and HER2(-) MDA-MB-231 cell derived exosomes. We also demonstrate the successful isolation of exosomes from a small cohort of breast cancer patient samples and identified that approximately 14-35% of their bulk population express HER2.
AB - Tumor-derived exosomes possess significant clinical relevance due to their unique composition of genetic and protein material that is representative of the parent tumor. Specific isolation as well as identification of proportions of these clinically relevant exosomes (CREs) from biological samples could help to better understand their clinical significance as cancer biomarkers. Herein, we present a simple approach for quantification of the proportion of CREs within the bulk exosome population isolated from patient serum. This proportion of CREs can potentially inform on the disease stage and enable non-invasive monitoring of inter-individual variations in tumor-receptor expression levels. Our approach utilises a Surface Plasmon Resonance (SPR) platform to quantify the proportion of CREs in a two-step strategy that involves (i) initial isolation of bulk exosome population using tetraspanin biomarkers (i.e., CD9, CD63), and (ii) subsequent detection of CREs within the captured bulk exosomes using tumor-specific markers (e.g., human epidermal growth factor receptor 2 (HER2)). We demonstrate the isolation of bulk exosome population and detection of as low as 10% HER2(+) exosomes from samples containing designated proportions of HER2(+) BT474 and HER2(-) MDA-MB-231 cell derived exosomes. We also demonstrate the successful isolation of exosomes from a small cohort of breast cancer patient samples and identified that approximately 14-35% of their bulk population express HER2.
UR - http://www.scopus.com/inward/record.url?scp=84979939322&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84979939322&partnerID=8YFLogxK
U2 - 10.1038/srep30460
DO - 10.1038/srep30460
M3 - Article
C2 - 27464736
AN - SCOPUS:84979939322
SN - 2045-2322
VL - 6
JO - Scientific Reports
JF - Scientific Reports
M1 - 30460
ER -
